View Older Stories View More Recent Stories
-
Eli Lilly Q1 earnings preview: analysts eye outlook for obesity drugs
-
Eli Lilly & Co. (LLY) call put ratio 1.1 calls to 1 put into quarter results
-
Eli Lilly & Co. (LLY) call put ratio 1.5 calls to 1 put into quarter results
-
Eli Lilly & Co. (LLY) call put ratio 1.3 calls to 1 put into quarter results
-
Eli Lilly (LLY) PT Lowered to $$1,058 at Leerink Partners
-
AI is starting to impact the pharma sector — These 2 stocks are seen as NT winners
-
Morgan Stanley Comments on Eli Lilly (LLY) Amid Premarket Volatility
-
Eli Lilly & Co. (LLY) shares trade lower on weak Foundayo launch
-
Hims & Hers expands platform to include Eli Lilly weight loss medications
-
Bernstein: Potential for Beat to Drive Eli Lilly (LLY) Stock
-
Rigel Pharmaceuticals regains rights as Lilly terminates license deal
-
Morgan Stanley Comments Eli Lilly (LLY) and Medicare GLP-1 Obesity Coverage
-
Eli Lilly and Novo Nordisk shares fall as CVS opts out of Medicare obesity drug coverage
-
CVS Health Opts Out Of Medicare Obesity Drug Coverage Model
-
UBS Reiterates Buy Rating on Eli Lilly (LLY)
-
Bernstein SocGen Reiterates Outperform Rating on Eli Lilly (LLY)
-
RBC Capital on Eli Lilly (LLY): Kelonia acquisition payment 'may appear full,' but strategically justified
-
RBC on Legend Biotech Corp. (LEGN): 'We Think Shares Remain Undervalued'
-
Eli Lilly & Co. (LLY) nears deal to acquire Kelonia Therapeutics - WSJ
-
Truist Securities Reiterates Buy Rating on Eli Lilly (LLY)
-
Guggenheim Reiterates Buy Rating on Eli Lilly (LLY)
-
Leerink Partners now expects Eli Lilly's (LLY) Foundayo in diabetes to be approved in 2H26
-
Walmart expands weight management services with virtual care platform
-
BMO Capital Reiterates Outperform Rating on Eli Lilly (LLY)
-
Eli Lilly to acquire CrossBridge Bio for up to $300 million
-
Leerink stays Outperform on Eli Lilly (LLY) after Jaypirca Ph3 results
-
Lilly's Jaypirca shows positive results in blood cancer trial
-
Bernstein on US Pharma and Biotech: Who might buy whom?
-
Eli Lilly & Co. (LLY) call put ratio 2 calls to 1 put as share price down 1.7%
-
RBC Capital 'Expecting GLP-1 Sales Strength' for Eli Lilly (LLY)
-
GoodRx offers Eli Lilly's new oral GLP-1 drug at $149 monthly
-
Lilly launches Foundayo oral GLP-1 weight loss pill in US market
-
Eli Lilly (LLY) Reiterated at Overweight by Cantor Fitzgerald Ahead of Foundayo Launch
-
AC Immune amends Lilly collaboration for tau drug development
-
Novo Nordisk says Wegovy pill shows greater weight loss than Lilly rival
-
Eli Lilly (LLY) PT Raised to $1,294 at BofA Securities
-
Leerink Partners reiterates Outperform on Eli Lilly (LLY) following orforglipron approval
-
Eli Lilly opposes push to pass Trump’s drug pricing deals into law, CEO tells CNBC
-
Truist Securities Reiterates Eli Lilly (LLY) at Buy on Foundayo approval, 'remain bullish on Lilly'
-
FDA approves Foundayo weight loss pill in record 50 days
-
Barclays on Eli Lilly (LLY): Centessa a 'sensible tuck-in' for neuroscience division
-
Eli Lilly & Co. (LLY) call put ratio 2.8 calls to 1 put after acquiring Centessa (CNTA)
-
BMO Capital on Eli Lilly (LLY): Centessa deal positive for shares; 'diversifying business ahead of any major LOEs'
-
Centessa shares surge after Lilly unveils $6.3 billion takeover deal
-
Wolfe: 'We're observing some reports of GLP-1 users refreshing their wardrobes as weight loss progresses'
-
Lilly partners with Insilico Medicine in AI drug discovery deal
-
Eli Lilly (LLY) PT Lowered to $1,163 at Guggenheim
-
Should you buy the dip in Novo Nordisk stock? Wall Street analyst answers
-
Lilly presents four-year data for EBGLYSS in atopic dermatitis study
-
Morgan Stanley on Eli Lilly (LLY) following scripts: 'We see ~6% upside to '26 M+Z ests'

